Descripciones mejoradas de Syndetics:

Drug therapy as an alternative to surgical intervention is becoming increasingly common. In the past five years, new anti-glaucoma agents have becoming increasingly effective. This edition will include new information on off-label prescribing and cap colors where they are mandated by the FDA (pink/white for steroid drops, grey for topical NSAIDS, etc.);There are now several new pharmaceutical agents being used to treat retinal diseases such as age-related macular degeneration (Macugen, Lucentis, Visudyne), while other drugs formerly prescribed have now been shown to be less effective. Intraocular infections are primarily treated with intravitreal medications. Additionally, the anti-allergy and dry eye markets continue to grow, with a new formulation of Allergan's Acular 0.5% (ketorolac tromethamine) and Elestat ophthalmic solution, its new antihistamine-mast cell stabilizer.

Notas de autor provistas por Syndetics

Douglas J. Rhee, MDAssistant ProfessorHarvard Medical SchoolAssociate Chief, Practice DevelopmentMassachusetts Eye & Ear InfirmaryBoston, Massachusetts USA Katheryn A. Colby, MD, PhDAssistant Professor Harvard Medical SchoolCornea ServiceMassachusetts Eye & Ear InfirmaryBoston, Massachusetts USA Christopher J. Rapuano, MDProfessorJefferson Medical CollegeDirector, Cornea ServiceWills Eye HospitalPhiladelphia, Pennsylvania USA Lucia Sobrin, MD, MPHAssistant ProfessorHarvard Medical SchoolMassachusetts Eye & Ear InfirmaryBoston, Massachusetts USA